Hadassah

Hadassah and Yale Researchers Find Peptide Prevents Disease in Mice

Thursday, Jun 13 2013

Researchers from the Hadassah University Medical Center's Department of Bone Marrow Transplantation, jointly with Yale University and BioIncept, an American-based biotechnology company, have discovered that a certain peptide released by a fetus during pregnancy, called a "pre-implantation factor" (PIF) is effective in preventing graft-versus-host disease (GVHD) in mice, following a bone marrow transplant.

Bone marrow transplants, performed to treat severe hematologic malignancies, the researchers explain, "often lead to potentially fatal, acute GVHD, despite attempts at better donor–recipient matching and/or use of immunosuppressive agents."

When a fetus releases PIF during its early stages of development (mainly during the first two trimesters), it enables the rooting of the fetus in its mother's uterus, regulating immune activity and preventing the mother's rejection of the fetus, without harming the mother's immune system. Given PIF's immune regulating properties and its effectiveness in developing maternal tolerance, it could logically have the potential to regulate the immune response in GVHD. In addition, the authors note that synthetic PIF treatment has proven effective in preventing immune attacks in nonpregnant models of autoimmunity.

In this study, the researchers transplanted bone marrow and spleen cells from donors into mice and then treated them with PIF for two weeks. Short-term PIF administration reduced acute GVHD and increased survival for up to four months following a transplant. This effect was coupled with decreased skin inflammation and decreased liver inflammation, as well as reduced colon ulceration--all without interfering with the positive effects of the transplant.

"Overall," the researchers concluded, "our data demonstrate that PIF protects against GVHD long term by reducing both target organ and systemic inflammation and by decreasing oxidative stress." This research joins other studies conducted by the Department of Bone Marrow Transplantation, which demonstrated the effectiveness of the peptide in preventing diabetes and central nervous system inflammation.

Since recent tests in the United States have successfully ruled out any toxic or negative side effects in healthy animals as a result of this peptide treatment, researchers can now take the next step and begin clinical trials in humans. According to Prof. Reuven Or, head of Hadassah's Department of Bone Marrow Transplantation, "In the next few months, Hadassah researchers will focus on preparing for the upcoming clinical trial and making sure we have all necessary documents and approvals in order to begin."

Read the abstract in the Biology of Blood and Marrow Transplantation Journal>>

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Tuesday, Apr 17 2018

Where are we with Stem Cells? Hadassah Pioneer Brings Us Up to Date

Many diseases involve the malfunctioning or dying of cells within the body.

READ MORE ›
alt_text

Tuesday, Apr 17 2018

Predicting Clinical Outcomes for Multiple Sclerosis Patients: Cutting-Edge Research at Hadassah

More than two million people--two to three times more women--have multiple sclerosis (MS)--the leading cause of neurological disability among young adults. What is their prognosis?

READ MORE ›
alt_text

Friday, Apr 13 2018

Hadassah Hospital Mount Scopus Hosts Conference to Mark Annual World Down Syndrome Day

Hadassah Hospital Mount Scopus hosted 200 people at the annual World Down Syndrome Day conference, held at the hospital in late March.

READ MORE ›
alt_text

Friday, Apr 13 2018

Hadassah Physicians Increase Number of Partial Thyroidectomies Following New ATA Guidelines

Following updated recommendations from the American Thyroid Association (ATA), Nir Hirschoren, M.D., of the Hadassah-Hebrew University Medical Center in Jerusalem...

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More